1453848-26-4
1453848-26-4 結(jié)構(gòu)式
基本信息
ERK激酶抑制劑(GDC-0994)
1-[(1S)-1-(4-氯-3-氟苯基)-2-羥基乙基]-4-[2-[(1-甲基-1H-吡唑-5-基)氨基]-4-嘧啶基]-2(1H)-吡啶酮
(S)-1-(1-(4-氯-3-氟苯基)-2-羥乙基)-4-(2 - ((1-甲基-1H-吡唑-5-基)氨基)嘧啶-4-基)吡啶-2(1H) - 酮
GDC-0994
EOS-60648
Ravoxertinib
GDC-0994
RAVOXERTINIB
RAVOXERTINIB (GDC-0994)
GDC 0994
GDC-0994
GDC0994
(S)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one
1-[(1S)-1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl]-4-[2-[(1-methyl-1H-pyrazol-5-yl)amino]-4-pyrimidinyl]-2(1H)-pyridinone
2(1H)-Pyridinone, 1-[(1S)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-[2-[(1-methyl-1H-pyrazol-5-yl)amino]-4-pyrimidinyl]-
物理化學(xué)性質(zhì)
制備方法
![2(1H)-Pyridinone, 1-[(1S)-1-(4-chloro-3-fluorophenyl)-2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-4-[2-[(1-methyl-1H-pyrazol-5-yl)amino]-4-pyrimidinyl]-](/CAS/20210111/GIF/1453854-96-0.gif)
1453854-96-0
1453848-26-4
步驟B：將粗制的(S)-1-(2-((叔丁基二甲基甲硅烷基)氧基)-1-(4-氯-3-氟苯基)乙基)-4-(2-((1-甲基-1H-吡唑-5-基)氨基)嘧啶-4-基)吡啶-2(1H)-酮（48 mg）溶解于乙酸乙酯（4 mL）中。在2分鐘內(nèi)緩慢滴加用HCl氣體飽和的乙酸乙酯溶液（1.0 mL）。反應(yīng)混合物在室溫下攪拌15分鐘，LCMS分析顯示原料完全消耗。將反應(yīng)混合物濃縮，得到油狀殘余物，通過制備型反相高效液相色譜（RP-HPLC）純化，得到(S)-1-(1-(4-氯-3-氟苯基)-2-羥基乙基)-4-(2-((1-甲基-1H-吡唑-5-基)氨基)嘧啶-4-基)吡啶-2(1H)-酮（20.8 mg，收率54.6%），為凍干粉末。1H NMR (400 MHz, (CD3)2SO) δ 9.58 (s, 1H), 8.60 (d, J = 5.1 Hz, 1H), 7.91 (t, J = 9.0 Hz, 1H), 7.58 (t, J = 8.1 Hz, 1H), 7.52-7.41 (m, 2H), 7.37 (d, J = 1.8 Hz, 1H), 7.14 (dd, J = 10.7, 5.1 Hz, 2H), 6.86 (dd, J = 7.3, 1.8 Hz, 1H), 6.27 (d, J = 1.7 Hz, 1H), 5.97 (dd, J = 7.7, 5.7 Hz, 1H), 5.31 (t, J = 5.2 Hz, 1H), 4.15 (m, 1H), 4.10-3.95 (m, 1H), 3.69 (s, 3H); LCMS m/z 441 (M + H)+。
參考文獻：
[1] Patent: WO2013/130976, 2013, A1. Location in patent: Paragraph 00399
[2] Journal of Medicinal Chemistry, 2016, vol. 59, # 12, p. 5650 - 5660
[3] Organic Process Research and Development, 2017, vol. 21, # 3, p. 387 - 398
[4] Patent: US2017/22183, 2017, A1. Location in patent: Paragraph 0143; 0161
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/05/22 | HY-15947 | GDC-0994 Ravoxertinib | 1453848-26-4 | 2mg | 990元 |
| 2025/05/22 | HY-15947 | GDC-0994 Ravoxertinib | 1453848-26-4 | 10mM * 1mLin DMSO | 1455元 |
| 2025/05/22 | HY-15947 | GDC-0994 Ravoxertinib | 1453848-26-4 | 5mg | 1500元 |
常見問題列表
| Target | Value |
|
ERK2
(Cell-free assay) | 0.3 nM |
|
ERK1
(Cell-free assay) | 1.1 nM |
GDC-0994有效抑制腫瘤細胞中磷酸-p90RSK。